AbbVie (ABBV) Competitors $222.29 +0.30 (+0.14%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$222.52 +0.23 (+0.10%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABBV vs. AMGN, GILD, MRNA, ABT, BMY, JNJ, LLY, MRK, PFE, and ZTSShould you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Zoetis (ZTS). These companies are all part of the "medical" sector. AbbVie vs. Its Competitors Amgen Gilead Sciences Moderna Abbott Laboratories Bristol Myers Squibb Johnson & Johnson Eli Lilly and Company Merck & Co., Inc. Pfizer Zoetis Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Do analysts recommend AMGN or ABBV? Amgen currently has a consensus target price of $304.43, suggesting a potential upside of 6.66%. AbbVie has a consensus target price of $222.68, suggesting a potential upside of 0.18%. Given Amgen's higher probable upside, equities analysts clearly believe Amgen is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.24AbbVie 0 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 4 Strong Buy rating(s) 2.93 Which has preferable earnings & valuation, AMGN or ABBV? AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$34.92B4.40$4.09B$12.2323.34AbbVie$58.33B6.73$4.28B$2.10105.85 Does the media favor AMGN or ABBV? In the previous week, AbbVie had 59 more articles in the media than Amgen. MarketBeat recorded 120 mentions for AbbVie and 61 mentions for Amgen. Amgen's average media sentiment score of 1.50 beat AbbVie's score of 1.28 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 55 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 90 Very Positive mention(s) 6 Positive mention(s) 16 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in AMGN or ABBV? 76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.8% of Amgen shares are held by company insiders. Comparatively, 0.3% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is AMGN or ABBV a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.0%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 312.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and lower payout ratio. Which has more risk & volatility, AMGN or ABBV? Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Is AMGN or ABBV more profitable? Amgen has a net margin of 18.96% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Amgen's return on equity.Company Net Margins Return on Equity Return on Assets Amgen18.96% 174.71% 13.12% AbbVie 6.45%699.66%13.64% SummaryAbbVie beats Amgen on 12 of the 20 factors compared between the two stocks. Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABBV vs. The Competition Export to ExcelMetricAbbVieLarge Cap Pharma IndustryMedical SectorNYSE ExchangeMarket Cap$393.01B$256.26B$5.80B$21.65BDividend Yield2.96%2.71%5.61%3.51%P/E Ratio105.8530.7480.5029.94Price / Sales6.734.75452.6059.78Price / Cash14.9013.8037.6624.98Price / Book116.9918.9515.754.59Net Income$4.28B$8.49B$3.30B$1.00B7 Day Performance1.78%0.83%5.35%0.81%1 Month Performance6.08%-0.06%7.28%5.30%1 Year Performance14.90%-9.32%80.79%14.58% AbbVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABBVAbbVie4.7726 of 5 stars$222.29+0.1%$222.68+0.2%+14.9%$393.01B$58.33B105.8555,000Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAMGNAmgen4.5548 of 5 stars$274.40-0.7%$304.43+10.9%-15.4%$147.73B$34.92B22.4428,000Positive NewsGILDGilead Sciences4.947 of 5 stars$112.54-1.8%$115.39+2.5%+35.9%$139.64B$28.75B22.4217,600News CoveragePositive NewsAnalyst ForecastInsider TradeMRNAModerna4.5279 of 5 stars$23.88+1.6%$41.81+75.1%-61.6%$9.29B$3.24B-3.175,800ABTAbbott Laboratories4.9382 of 5 stars$131.40-1.7%$144.47+9.9%+19.8%$228.70B$41.95B16.47114,000News CoveragePositive NewsDividend AnnouncementBMYBristol Myers Squibb4.9279 of 5 stars$46.34+0.3%$56.38+21.7%-8.8%$94.32B$47.70B18.6934,100Trending NewsDividend AnnouncementAnalyst RevisionJNJJohnson & Johnson4.7042 of 5 stars$177.49-0.3%$176.29-0.7%+7.2%$427.46B$90.63B18.98138,100Trending NewsAnalyst ForecastLLYEli Lilly and Company4.9971 of 5 stars$748.26-0.9%$941.35+25.8%-18.2%$708.20B$53.26B48.9147,000Trending NewsAnalyst ForecastMRKMerck & Co., Inc.4.9993 of 5 stars$81.07-2.1%$107.44+32.5%-30.5%$202.50B$64.17B12.4975,000Trending NewsAnalyst DowngradePFEPfizer4.9882 of 5 stars$23.98+0.5%$28.12+17.3%-18.3%$136.34B$63.63B12.7681,000Trending NewsAnalyst UpgradeZTSZoetis4.8603 of 5 stars$146.34-1.3%$200.88+37.3%-24.3%$64.85B$9.26B25.1913,800Positive News Related Companies and Tools Related Companies AMGN Competitors GILD Competitors MRNA Competitors ABT Competitors BMY Competitors JNJ Competitors LLY Competitors MRK Competitors PFE Competitors ZTS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABBV) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
